A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Clinical trial NCT04539938 · COMPLETED
Trial details
- NCT number
- NCT04539938
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-01
- Primary completion
- 2024-07-15
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.